Juno Therapeutics executives under investigation
Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of Juno Therapeutics breached their fiduciary duties to Juno and its shareholders by exposing Juno to civil liability for failing to disclose patient deaths in the Phase II/ROCKET trial of its leading product candidate, JCAR015, during the period June 24, 2016 to November 22, 2016. A motion to dismiss a class action lawsuit against Juno and its CEO, CFO and Chief Medical Officer was recently denied by the U.S. District Court for the Western District of Washington. The class action alleges that the defendants recklessly failed to tell investors that patients were dying from toxic side effects associated with JCAR015 during the treatment's Phase II trial. The plaintiffs allege that the defendants falsely represented that the deaths were attributable to the use of fludarabine in combination with JCAR015 when they actually knew that fludarabine had nothing to do with the deaths, and instead were attributable to JCAR015 alone. Juno is exposed to substantial potential liability through the class action. The Schubert Law Firm's investigation concerns when and how much certain of Juno's officers and directors knew or should have known about role of JCAR015 in the patient deaths that occurred during the Phase II trial of JCAR015, and that the Company's representations regarding the role of fludarabine were false or misleading.